<span item_type="fundamental" item_id="bca3c8389f87988bc0026da40864728e" counter_id="ST/US/RGBP" env="prod"></span><span item_type="announcement" item_id="516792817427226369" env="prod"></span><p>Revenue: As of FY2025 Q1, the actual value is USD 59.07 K.</p><p>EPS: As of FY2025 Q1, the actual value is USD -0.13.</p><p></p><h3>Segment Revenue</h3><ul><li>Total revenue for the three months ended December 31, 2024, was $59,065, consistent with the same period in 2023. This includes $27,425 from related parties and $31,640 from licenses granted to Oncology Pharma, Inc.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1589150/000164117225011206/form10-q.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li>Operating expenses decreased to $120,443 for the three months ended December 31, 2024, from $181,847 in the same period in 2023. The decrease was primarily due to reduced consulting and professional fees and the absence of research and development expenses in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1589150/000164117225011206/form10-q.htm"></span></li><li>Loss from operations was $61,378 for the three months ended December 31, 2024, compared to $122,782 for the same period in 2023.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1589150/000164117225011206/form10-q.htm"></span></li><li>Net loss for the three months ended December 31, 2024, was $515,384, significantly higher than the net loss of $144,933 for the same period in 2023, primarily due to a derivative loss of $416,016 recognized in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1589150/000164117225011206/form10-q.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Net cash used in operating activities for the quarter ended December 31, 2024, was $66,379, a decrease from $162,336 in the same period in 2023.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1589150/000164117225011206/form10-q.htm"></span></li><li>Net cash provided by financing activities for the quarter ended December 31, 2024, was $65,799, primarily from proceeds from notes payable.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1589150/000164117225011206/form10-q.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li>Derivative liability increased to $1,820,106 as of December 31, 2024, from $1,404,090 as of September 30, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1589150/000164117225011206/form10-q.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li>The company has incurred significant operating losses and negative cash flows from operations since inception, with an accumulated deficit of approximately $21 million as of December 31, 2024. The company is dependent on obtaining additional working capital funding from the sale of equity and/or debt securities to continue operations.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1589150/000164117225011206/form10-q.htm"></span></li><li>As of December 31, 2024, the company had cash of $135 and a net working capital deficit of $5,696,776, indicating substantial doubt about the company’s ability to continue as a going concern without additional funding.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1589150/000164117225011206/form10-q.htm"></span></li></ul>

Regen BioPharma, Inc. | 10-Q: FY2025 Q1 Revenue: USD 59.07 K